Review: Significance of, and optimal screening for, HER-2 gene amplification and protein overexpression in breast carcinoma

Annals of Clinical and Laboratory Science

Volumn 31, Issue 4, 2001, Pages 349-358

  Funkhouser, W K ^a   Kaiser Rogers, K ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Cancer chemotherapy; HER 2 gene amplification; HER 2 protein overexpression

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ONCOPROTEIN; POLYCLONAL ANTIBODY; POLYCLONAL ANTIBODY A4085; PROTEIN TYROSINE KINASE; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER STAGING; CELL TRANSFORMATION; CHROMOSOME 17; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC SCREENING; HUMANS; RECEPTOR, ERBB-2;

EID: 0034780374     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Cancer statistics
2. Breast carcinoma
3. Should HER2 status be routinely measured for all breast cancer patients?
4. Role of HER2 gene overexpression in breast carcinoma
5. HER-2/neu (c-erb-B2) gene and protein in breast cancer
6. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
7. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
8. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
9. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and inter-observer reproducibility in invasive breast carcinoma
10. HER2 testing: Laboratory, technical and clinical considerations
11. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
12. Herceptin (trastuzamab) in advanced breast cancer
13. The type 1 growth factor receptor family: New ligands and receptors and their role in breast cancer
14. The stimulation of epidermal proliferation by a specific protein (EGF)
15. Isolation and structure of urogastrone and its relationship to epidermal growth factor
16. Human epidermal growth factor: Isolation and chemical and biological properties
17. Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro
18. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
19. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
20. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB- 1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma
21. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
22. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas
23. Molecular cloning of the neu gene: Absence of gross structural alteration in oncogenic alleles
24. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors
25. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family
26. The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen
27. HER4-mediated biological and biochemical properties in NIH 3T3 cells. Evidence for HER1-HER4 heterodimers
28. The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells
29. A neu acquaintance for erbB3 and erbB4: A role for receptor heterodimerization in growth signaling
30. The neu-oncogene: Signal transduction pathways, transformation mechanisms, evolving therapies
31. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
32. Assessment of HER2 status in breast cancer: Why, when and how?
33. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells
34. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor
35. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
36. A subdomain in the transmembrane domain is necessary for p185neu* activation
37. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: Implications for human breast cancer
38. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message
39. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
40. Chromosome-specific aneusomy in carcinoma of the breast
41. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
42. Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry
43. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: A multicenter portability study
44. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
45. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells
46. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer
47. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
48. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases
49. Increased HER2 with U.S. Food and Drug Administration-approved antibody
50. Optimization of immunohistochemical detection of ErbB2 in human breast cancer
51. c-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples
52. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement
53. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
54. Multinational study of efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
55. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
56. First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: A preliminary report
57. Immunohistochemical assays for HER2 overexpression
58. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays
59. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system
60. Quantitative PCR analysis of c-erb B-2 (HER2/neu) gene amplification and comparison with p 185 (HER2/neu) protein expression in breast cancer drill biopsies
61. Evaluation of the United States Food and Drug Administration-approved scoring and test system of Her-2 protein expression in breast cancer
62. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer
63. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
64. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
65. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
66. Closing remarks and treatment guidelines